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Abstract
Objective. Patient-reported outcomes (PROs) are increasingly accepted to be among the major tools for
outcome assessment in rheumatic disorders. In this study we aimed to assess quality of life (QoL), dis-
ability, anxiety and depression in patients with Takayasu’s arteritis (TAK).
Methods. Patients followed with the diagnosis of TAK (n = 165) and healthy controls (HCs) (n = 109) were
enrolled to the study. The 36-item Short Form Health Survey (SF-36) and hospital anxiety and depression
scales (HADS) were used to assess QoL and mental status together with HAQ for disability.
Results. In SF-36 subscale assessment, all items were observed to be statistically lower in TAK patients;
similarly HAQ scores were also higher (P<0.001) in this group. In mental assessment, anxiety was found
to be more common in TAK patients [90 (54.5%) vs 38 (34.9%), P = 0.001]. Depression also tended to be
higher in TAK patients [70 (66.7%) vs 35 (33.3%)], without reaching significance (P = 0.086). Most of the
SF-36 subgroup parameters were lower in TAK patients with active disease. Patients having anxiety and
depression or with high HAQ scores reported worse SF-36 scores. In multivariate analysis, HADS-A,
HADS-D and HAQ were associated with most SF-36 subscales.
Conclusion. PROs demonstrate that not only general health but also physical and social functioning with
physical role limitations and mental health parameters were impaired in TAK. Our results, especially in
active disease, suggest that PROs such as SF-36 can be core domains of disease assessment in TAK,
similar to ANCA-associated vasculitides.
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Introduction
Takayasu’s arteritis (TAK) is a chronic, inflammatory dis-
order involving large vessels, especially the aorta and its
main branches [13]. Histopathologically it is character-
ized by panarteritis with an inflammatory infiltrate that is
predominantly lymphoblastic, with granuloma formation
and giant cells involving the media and adventitia [4]. As
a result of inflammation, intimal hyperplasia, vascular
stenosis and rarely aneurysm formation can occur [5, 6].
Clinical presentation of TAK is varied and can occur with
non-specific symptoms such as fever, myalgia, arthralgia,
weight loss or ischaemia, and vessel stenosis-related
symptoms (upper extremity claudication, hypertension,
carotidynia, syncope, dizziness and visual symptoms) [4].
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Quality of life (QoL) is increasingly accepted to be a
major domain for the assessment of patients with chronic
disorders. The 36-item Short Form Health Survey (SF-36)
is the most frequently used generic QoL tool in rheumatic
diseases [7, 8]. Recent studies have suggested that QoL
parameters are impaired in small to medium vessel sys-
temic vasculitides [914] and also in TAK [15, 16].
Functional status is another area of life impact in inflam-
matory disorders, with generic tools developed for inflam-
matory arthritides but rarely studied in vasculitides [11].
In addition, mood and other mental changes are also a
significant problem in chronic medical conditions and may
impact the QoL of vasculitis patients.
With this background, the aims of this study were to (i)
evaluate QoL and functional disability in TAK patients
compared with healthy controls (HCs), (ii) assess some
psychometric properties and (iii) examine the role of dis-




One hundred and sixty-five consecutive patients (153
female, 12 male) followed with the diagnosis of TAK at
the rheumatology outpatient clinics of nine university hos-
pitals in Turkey were enrolled in this multicentre, cross-
sectional study. All patients fulfilled the proposed classifi-
cation criteria of the ACR for Takayasu’s arteritis [17] and
were subclassified according to the angiographic classifi-
cation for TAK [18]. One hundred and nine age- and sex-
adjusted HCs (99 female, 10 male) were randomly
selected from healthy people who accompanied TAK pa-
tients attending the rheumatology outpatient clinics.
Having no symptoms of any disorder and not being a
member or close relative of the patient’s family were the
inclusion criteria for the control group. The study was
approved by the Ethical Committee of Marmara
University Medical School and all patients and controls
gave written informed consent. Exclusion criteria were
being < 18 years of age, having a personal history of psy-
chiatric disease and being unable to give written informed
consent. The demographic and clinical data of the pa-
tients were recorded and TAK patients were evaluated
by physician’s global assessment (PGA, active/inactive)
and modified Kerr activity criteria for their disease activity
[19]. Active disease was defined if two of the following
were positive: (i) systemic features with no other cause,
(ii) elevated ESR, (iii) features of vascular ischaemia or in-
flammation (claudication, diminished or absent pulses,
bruit, vascular pain or asymmetric blood pressure) and
(iv) typical angiographic features [19].
QoL, functional status and mental assessment
QOL was evaluated with a validated Turkish translation of
the SF-36 [20]. The SF-36 contains eight domains, four
physical (physical functioning, physical role limitation,
bodily pain and general health) and four mental (social
functioning, emotional role limitation, mental health and
vitality). On the basis of these separate subscales, phys-
ical and mental component summary scores can be cal-
culated. The scales and summary scores range from 0 to
100, with higher scores indicating better QoL [15, 21, 22].
No validated tool is available for functional assessment
in vasculitides. Although primarily developed for inflam-
matory rheumatological diseases with joint involvement
such as RA, HAQ was suggested to be a useful tool for
all rheumatic diseases by Pincus et al. [23] and was
chosen for our study.
The Hospital Anxiety and Depression Scale (HADS) [24]
was used to assess the mental status. HADS scores of
810 indicate possible, scores of 1114 indicate probable
and scores of 1521 indicate extreme cases of depression
and anxiety [11, 25].
Statistical analysis
Comparisons between groups were made by using para-
metric Student’s t test in normal distributions and non-
parametric MannWhitney U tests in non-normal distribu-
tions of variables.The 2 test was performed to compare
HADS-A, HADS-D and HAQ scores between the groups.
In addition associations between the PGA and Kerr activ-
ity, HADS-A and HADS-D scores were evaluated by 2
test. Internal consistency (reliability) of the HAQ and SF-
36 were evaluated using Cronbach’s a (each subscale
against the HAQ total score). Correlation between HAQ
scores and SF-36 physical disability scores for concurrent
validity were assessed using Spearman’s correlation co-
efficient. Interobserver reliability of SF-36 subscales was
assessed with the Wilcoxon test.
Univariate linear regression analyses were used to de-
termine the relationships between age, disease duration,
ESR, CRP and SF-36 subgroups. Multivariate logistic re-
gression models using a stepwise backward elimination
approach were fitted to determine the ability of HADS-A,
HADS-D, HAQ and PGA to independently predict SF-36
scores. Impaired SF-36 subgroup scores on each SF-36
subscale were defined as values lower than the mean
values observed for the entire study population.
P<0.05 was considered statistically significant. All stat-
istical analysis was performed by using the SPSS 11.5
statistical package programme (Chicago, IL, USA).
Results
Demographic and clinical features
Patient characteristics are shown in Table 1. The mean
(± S.D.) age was 41.3 ± 12.1 and 40.4 ± 10.3 years in TAK
and HC, respectively (P> 0.05). The mean disease dur-
ation was 8.73 ± 7.72 years. Fifty-three (31.2%) patients
had type I, 28 (17%) had type II, 10 (6.1%) had type III,
11 (6.7%) had type IV and 63 (38.1%) had type V angio-
graphic disease. While 144 (87.2%) patients were taking
combination treatment with immunsuppressives and cor-
ticosteroids, 6 (3.6%) patients were taking corticosteroids
only and 15 (9.1%) were followed without any medication.
www.rheumatology.oxfordjournals.org 1899
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At the time of the study, 71 (43%) patients were ac-
cepted as having active disease according to the PGA.
According to criteria defined by Kerr et al., 42/165 patients
were active (25.4%), with a significant association
observed between Kerr scores and PGA (P< 0.001). The
median ESR was 21.5 (1110) mm/h and the median CRP
level was 0.5 (0.0254.5) mg/dl.
SF-36 scores
In the SF-36 assessment, all items were observed statis-
tically lower in TAK patients than HCs (P< 0.001) (Fig. 1).
The SF-36 subscales showed high internal consistency
with a Cronbach’s a value of 0.85 (range 0.820.85), indi-
cating a high reliability of the measure when used in TAK
patients. Inter-observer reliability was done by two obser-
vers in 13 TAK patients and a good inter-observer reliabil-
ity was also observed at all SF-36 scores (P> 0.05).
Assessment of functional disability with HAQ
The HAQ score was 51 in 21 patients (12.7%) in the TAK
group, whereas all HC scores were <1 (P< 0.001) (mean
HAQ scores were 0.49 ± 0.84 vs 0.08 ± 0.15, P< 0.001). As
HAQ is mainly validated to measure physical functioning
in RA and not validated as a disability measure in TAK, we
assessed the reproducibility and reliability of HAQ in our
patient population. Cronbach’s a values ranged from 0.93
to 0.94, indicating a high reliability of the measure when
used in TAK patients. Concurrent validity was evaluated
by correlating the total HAQ score with the SF-36 physical
functioning subscale score. There was a significant nega-
tive correlation between the two measures (r =0.69,
P< 0.001), supporting that HAQ also has a high concur-
rent validity in TAK patients.
Mental health in TAK
Of the 165 TAK patients who completed the HADS, 19.3%
scored as possible, 20.6% as probable and 2.4% as ex-
treme cases of depression and 25.4% scored as possible,
20% as probable and 9% as extreme cases of anxiety.
When the cut-off value was taken as 8, anxiety was found
to be significantly higher in TAK patients than in HCs [90
(54.5%) vs 38 (34.9%), P = 0.001]. Depression also tended
to be higher in TAK patients [70 (66.7%) vs 35 (33.3%)],
without reaching statistical significance (P = 0.086) (mean
anxiety scores were 8.28 ± 4.08 vs 6.2 ± 3.86 and mean
depression scores were 6.81 ± 4.18 vs 5.8 ± 3.83,
respectively).
Disease activity and PROs
Defining active disease according to PGA, most of the SF-
36 subgroup parameters, except mental health, were
observed to be statistically lower in active TAK patients
(P< 0.05) (Fig. 2, Table 2). However, the HADS-A, HADS-
D and HAQ scores were not different between the active
and inactive groups. Anxiety was found in 47 patients
(50%) with inactive disease and in 43 patients (60.6%)
with active disease (P> 0.05). Depression was present
in 37 (39.4%) and 33 (46.5%) patients, respectively
(P> 0.05). Patients having anxiety and depression or
with high HAQ scores reported worse SF-36 scores
(P< 0.001, P< 0.001 and P< 0.05, respectively) (Table 2).
Predictors of QoL in TAK patients
We also assessed the factors associated with QoL in TAK
patients with uni- and multivariate analysis. The results of
the univariate analysis are shown in Table 3 and the multi-
variate analysis in Table 4. There was no association be-
tween acute-phase response (ESR or CRP levels) and
SF-36 scores (P> 0.05), except physical role limitation
(b=0.16, P = 0.03). Age was negatively associated with
some SF-36 parameters [physical functioning (b=0.31,
P< 0.001), emotional role limitation (b=0.18, P = 0.02)
TABLE 1 Demographic features of TAK patients
Gender, female/male 153/12
Age, years 41.3 (12.1)
Disease duration, years 8.73 (7.72)
Disease subset, n (%)
Type I 53 (31.2)
Type II 28 (17)
Type III 10 (6.1)
Type IV 11 (6.7)
Type V 63 (38.1)
Treatment, n (%)
MTX plus MP 75 (45.4)
AZA plus MP 51 (30.9)
CYC plus MP 5 (3)
LEF plus MP 3 (1.8)
MMF plus MP 2 (1.2)
CsA plus MP 1 (0.6)
Infliximab 7 (4.2)
Glucocorticoids alone 6 (3.6)
Without treatment 15 (9.1)
ESR, median (minmax range), mm/h 21.5 (1110)
CRP, median (minmax range), mg/dl 0.5 (0.0254.5)
MP: methyprednisolone; CsA: ciclosporin-A. Values are pre-
sented as mean (S.D.), unless otherwise indicated.
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and pain (b=0.16, P = 0.03)] that were not significant in
practice. When multivariate analysis was performed,
HADS-A, HADS-D and HAQ were associated with most
SF-36 subscales (Table 4).
Discussion
In this study we showed that all aspects of SF-36, both
physical and mental, were impaired in TAK patients com-
pared with age- and sex-matched HCs. Similarly, our
patients had impaired physical function and higher anxiety
scores, suggesting that TAK also might affect QoL, similar
to small to medium vessel vasculitides. Disease assess-
ment in TAK has important challenges, as recently dis-
cussed [26, 27]. Being a chronic, slowly progressive,
large vessel vasculitis with usually limited constitutional
features, it may be difficult to determine the impact of
TAK on patient QoL. Physicians following TAK patients
usually focus on vascular outcomes such as narrowing
or occlusion, using mainly various imaging techniques to
assess vascular patency. The most cited Kerr criteria for
disease activity involves constitutional features, bruits,
acute-phase response and imaging as parameters of
active disease. A new effort to assess activity by a com-
posite index of clinical manifestations without imaging or
acute-phase response has also been shown to have im-
portant limitations [28]. However, recent studies have
demonstrated that physician and patient expectations
















Score <8 66.2 (23.4) 61.3 (42.1) 60.0 (34.1) 69.2 (24.6) 59.8 (29.1) 55.5 (19.5) 68.2 (15.1) 51.7 (24.9)
Score 58 48.6 (24.8) 28.9 (38.2) 39.8 (33.5) 49.7 (25.1) 46.4 (30.3) 32.8 (18.1) 52.0 (18.4) 33.9 (20.8)
P value <0.001 <0.001 <0.001 <0.001 0.006 <0.001 <0.001 <0.001
Anxiety
Score <8 67.4 (23.4) 65.2 (41.3) 65.4 (31.7) 71.4 (26.4) 64.7 (29.5) 58.6 (19.5) 72.0 (13.8) 55.9 (23.2)
Score 58 51.7 (24.9) 33.3 (40.1) 40.1 (34.0) 52.6 (23.7) 45.3 (28.1) 35.3 (18.0) 52.5 (17.0) 34.4 (21.2)
P value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
HAQ
Score <1 64.0 (21.1) 53.3 (42.7) 54.9 (35.3) 65.2 (24.8) 59.0 (28.4) 48.9 (21.4) 63.3 (17.2) 47.4 (23.7)
Score 51 23.1 (23.8) 9.5 (26.7) 28.3 (24.1) 33.1 (20.9) 21.3 (20.4) 25.9 (14.0) 48.7 (21.3) 22.9 (18.7)
P value <0.001 <0.001 0.001 <0.001 <0.001 <0.001 0.003 <0.001
PGA
Inactive 63.4 (24.3) 61.8 (42.1) 56.6 (34.2) 67.1 (25.7) 59.4 (29.0) 51.0 (21.6) 62.6 (18.3) 48.2 (22.9)
Active 52.7 (25.7) 29.2 (38.2) 44.8 (35.6) 53.2 (25.8) 47.1 (30.7) 39.2 (20.8) 59.9 (18.4) 38.8 (25.8)
P value 0.01 <0.001 0.02 0.001 0.008 0.001 0.34 0.009
All analysis were performed with MannWhitney U test. Values are presented as mean (S.D.), unless otherwise indicated.















Age 0.31* 0.15 0.18** 0.14 0.16** 0.09 0.01 0.04
Disease duration 0.13 0.02 0.05 0.09 0.09 0.15** 0.13 0.11
ESR 0.11 0.16** 0.12 0.13 0.12 0.06 0.07 0.04
CRP 0.003 0.10 0.06 0.009 0.09 0.06 0.05 0.10
*P< 0.001, **P< 0.05.
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might differ for the outcome and treatment effects.
Fatigue, for example, is commonly described by patients
as the major disabling feature of inflammatory disorders,
whereas it is rarely employed as a major outcome tool in
routine follow-up or clinical studies. For this reason,
OMERACT study groups emphasize the importance of
PROs as core domains of clinical assessment in clinical
trials. The OMERACT vasculitis study group recently
placed SF-36 for QoL assessment among the four core
domains (along with patient-reported outcomes, disease
activity, damage and mortality) for disease assessment in
ANCA-associated vasculitis [29].
Our results with SF-36 for QoL are similar to those of
two previous studies in TAK. Akar et al. [15] first reported
that QoL parameters are impaired in TAK patients com-
pared with HCs, without any differences between TAK, RA
and ankylosing spondylitis patients. SF-36 subscales had
high internal consistency, indicating high reliability for the
measurement of QoL in TAK. No significant correlation
between ESR or CRP levels and SF-36 parameters was
observed, similar to our study. However, in contrast to our
results, no correlation was present between the disease
activity and SF-36 parameters. In another study,
Abularrage et al. [16] showed that QoL is impaired in
TAK patients compared with HCs and other chronic dis-
eases associated with peripheral vascular disease, includ-
ing diabetes mellitus, hypertension and coronary artery
disease. The SF-36 has also been studied for small to
medium vessel vasculitis and has been shown to be im-
paired in granulomatosis with polyangiitis (GPA) and
microscopic polyangiitis [3033]. Tomasson et al. [34]
showed that improvement in the BVAS was also reflected
in both the physical and mental components of the SF-36,
suggesting that the SF-36 can be used to assess disease
activity. However, studies on large vessel vasculitis such
as GCA are limited and are controversial [35]. A major
criticism for generic PRO tools is their possible lack of
sensitivity to the areas of life impact that might be specific
to the health condition. Hellmann et al. [36] studied do-
mains of QoL important to GCA patients and found vision-
related impairment described to be the most important
item by patients. Similarly, compared with other vasculi-
tides, TAK has some major different impacts associated
with large-vessel involvement such as extremity claudica-
tion, and some features not covered by standard QoL in-
struments such as SF-36 should be assessed by focus
group studies.
We chose HAQ as the tool for assessing functional
status in our study, which was mainly devised for inflam-
matory rheumatological disorders with joint involvement.
We validated HAQ in our study and significant differences
were present between the patients and controls.
However, as only a difference of around 0.5 units was
observed (close to the minimum clinically detectable dif-
ference of 0.22 in RA) [37], HAQ might have a limited value
for disease assessment in TAK. This might be associated
with the nature of TAK, which usually causes very limited
impairment in the activities of daily life. New tools that
emphasize upper extremity claudication should be de-
veloped to use for TAK. Similarly, damage assessment
through the Vasculitis Damage Index (VDI) or other dis-
ease-specific instruments might also be useful for this
purpose.
To our knowledge, our study is the first to evaluate
mental health in TAK. When we evaluated anxiety and
depression scores with HADS, only anxiety seems to be
impaired significantly. Depression was also found to be
slightly higher in TAK patients, without a significant
difference. These results suggest a milder impairment of
psychological status in TAK compared with other inflam-
matory disorders such as SLE and RA, where depression
is commonly observed [38, 39]. The patient-reported out-
comes,resence of depression is also reported to be 22%
in one study in GPA, which is unassociated with disease
activity [40, 41]. However, we observed that psychological
status (both anxiety and depression) is associated with
the SF-36 in multivariate analysis. Anxiety seems to be a
continuous feature of mental health in TAK, possibly due
to long-term consequences that disturb mental status,
which might be accompanied by mild depression. The
mental component of the SF-36 possibly reflects this
TABLE 4 Multivariate logistic regression of factors asso-
ciated with SF-36
b S.E. P value Odds ratio
Physical
functioning
HAQ 2.54 0.77 0.01 12.7
Role limitation
(physical)
HADS-A 0.85 0.39 0.03 2.35
HADS-D 0.92 0.40 0.02 2.52
HAQ 1.99 0.78 0.01 7.37
PGA 1.35 0.37 <0.001 3.86
Role limitation
(emotional)
HADS-A 1.54 0.40 <0.001 4.69
HADS-D 0.79 0.40 0.04 2.20
HAQ 2.03 0.80 0.01 7.62
PGA 0.85 0.38 0.02 2.34
Social
functioning
HADS-D 1.02 0.35 0.004 2.78
HAQ 2.02 0.66 0.002 7.59
PGA 0.79 0.35 0.02 2.21
Pain
HADS-A 1.13 0.34 0.001 3.10
HAQ 2.02 0.78 0.01 7.54
PGA 0.84 0.35 0.01 2.37
Vitality
HADS-A 1.99 0.40 <0.001 7.30
HADS-D 1.14 0.41 0.006 3.31
PGA 1.07 0.40 0.007 2.93
Mental health
HADS-A 1.99 0.39 <0.001 7.33
HADS-D 1.14 0.39 0.004 3.13
General health
HADS-A 1.63 0.35 <0.001 5.13
HAQ 1.46 0.67 0.03 4.34
1902 www.rheumatology.oxfordjournals.org
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mental status, with a general lower QoL of the patients in
both remission and relapses of the disease course.
Disease activity was observed to be significantly asso-
ciated with most of the SF-36 parameters, suggesting that
disease activity affects QoL and mental and functional
status in TAK patients. In this respect, any clinical trial
for TAK in future studies should also incorporate PROs,
especially the SF-36, as a major outcome parameter.
A limitation of our study is the fact that both QoL and
mental status can be affected by many residual confound-
ing factors (such as degree of fatigue, socioeconomic
status, education, impact of treatment and drug compli-
ance) that we have not analysed, which might have
caused biases in our interpretation of the results.
Especially for psychometric assessment, other PRO
tools might be incorporated to define the mental status
and associated factors better. The cross-sectional
nature of our study and its hospital-based population
might also have influenced our results. However, we
assume that, due to its complicated clinical course and
rare presence, most TAK cases are referred to specialized
centres in Turkey. Finally, there can be a clinical vs stat-
istical difference in our PRO measurements. Some of the
observed differences might have limited value as a
clinically important difference compared with controls.
Disease-specific instruments developed from patient
focus groups will show the real impact of our results.
In conclusion, QoL parameters are impaired in patients
with TAK and remission of disease activity is associated
with better QoL. As disease activity is also associated with
anxiety and depression, supportive help for these do-
mains of health seem to be important for better QoL.
Finally, mild impairment of functional status with HAQ
should be better assessed with new tools in TAK.
Rheumatology key messages
. QoL is impaired in TAK and is associated with
active disease.
. A higher anxiety score and a mild functional impair-
ment are also observed in TAK.
Disclosure statement: The authors have declared no
conflicts of interest.
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